MEDICARE FOUNDATION - UK’s Post

During this #ILCA24 session, chaired by Bruno Sangro and Joyceline Lee, you will navigate the complexities and strategies to manage unresectable liver localised with leading experts bringing their insights from the East and the West, including Hong Kong and the USA. ➡️Riad Salem will explore the evolving landscape of Selective Internal Radiation Therapy. He will analyse the story of SIRT and discuss whether recent efficacy data should overshadow our memory of prior failed trials. ➡️Stephen Chan will discuss the latest advancements in "Immune Modulation for BCLC B: Combining ICI and Transarterial Treatments" highlighting innovative approaches to enhance patient outcomes. ➡️Marina Baretti will uncover the role of locoregional therapies in patients with intrahepatic cholangiocarcinoma (iCCA) and their potential impact on treatment strategies. ➡️Finally, Edward Kim will provide critical insights into patient selection for LRT where he will explain how to define TACE/TARE Unsuitable in 2023 and understand the criteria for appropriate treatment options. Register here to join the conversation and connect with international specialists: https://lnkd.in/dMhXvgHq

From sci-fi to reality → 👁️ transplants to restore vision Advanced Research Projects Agency for Health (ARPA-H) awarded $47 million to the project Human Eye-allotransplantation Innovation Advancement (THEIA), led in part by USC Roski Eye Institute, to supercharge bringing eye transplantation forward to clinical trial.

📈 Patients of physicians with higher adenoma detection rates during colonoscopy often have a lower risk of #colorectal cancer after screening #colonoscopy. 🔎 A recent observational study sought to determine if there is a correlation between the improvement of ADR and lower rates of CRC in patients who undergo colonoscopy:

📊 Are #ARSIs related to #cardiovascular events in advanced #ProstateCancer? ✅ Check out this research from Omar El-Taji, MBChB, MRes, and colleagues to learn more:

📊 Are #ARSIs related to #cardiovascular events in advanced #ProstateCancer? ✅ Check out this research from Omar El-Taji, MBChB, MRes, and colleagues to learn more:

Having benefitted from radiation therapy - the treatment times (often as short as ten minutes) are short relative to travel times even if you live near or even in a capital city. This seems to sum up the modern medicine big equipment challenge for Australia. We are a big country with long travel times and so applying an economic test rather than making an equity based decision will inevitably give the wrong answer for regional populations. Healthcare can never be a simple economic decision if you believe in fairness.

This open access paper describes the results of a study evaluating a peptide array for cardiac autoantibodies in #heart transplant recipients during acute cellular #rejection. #TXPforAll #Med #OpenAccess tinyurl.com/ymj346s6

We’re thrilled to share more encouraging updates from Neurizon Therapeutics’ Open-Label Extension (OLE) Study in patients with ALS. The latest data reveals that treatment with NUZ-001 remains well-tolerated and continues to demonstrate promising results in slowing disease progression and extending life expectancy compared to untreated matched controls. Our commitment to advancing this innovative therapy remains stronger than ever as we work to bring hope and new possibilities to the ALS community.   📖 Read the full press release here: https://lnkd.in/e-e2ydzY #ALS #NeurodegenerativeDiseases #NeurizonTherapeutics #HorizonOfHope

👀 Check out this research from Jonathan D. Tward, MD, PhD, and colleagues on the benefit of adding #ADT to #RT as a function of the personalized clinical #CCR score to ascertain the 10-year #metastasis risk for #ProstateCancer. 🧠 Learn More:

Research progress in Vienna 🇦🇹: CONQUEST investigators unite to tackle scleroderma and ILD. In Vienna, dedicated physicians from Europe discussed CONQUEST's progress, participated in training sessions, and shared insights. CONQUEST, a groundbreaking global platform clinical trial developed by the Scleroderma Research Foundation, aims to accelerate new treatment options for scleroderma. This international collaboration between participants is essential in creating a global network of scleroderma treatment centers. In its current stage, the primary objective of CONQUEST is to accelerate the evaluation of the treatments for interstitial lung disease (ILD) secondary to scleroderma (SSc-ILD). CONQUEST is currently enrolling patients with SSc-ILD. We encourage eligible individuals to consider participating in this groundbreaking study! Learn more about CONQUEST: https://bit.ly/46LaZU0 With ILD Day just around the corner on September 18, it’s important to remember that nearly 15% of people with scleroderma also have ILD. The Scleroderma Research Foundation is involved in this important day of awareness, alongside nine partner organizations. #ILDDay #SclerodermaAwareness #CONQUEST